Last updated: February 19, 2026
This report provides an in-depth analysis of Brazilian patent application BR112019025625, detailing its scope, key claims, and the competitive patent landscape. The patent, filed by AstraZeneca AB, concerns novel crystalline forms of the pharmaceutical compound Osimertinib mesylate. This analysis is critical for stakeholders assessing market entry strategies, potential infringement risks, and R&D investment opportunities within the Brazilian oncology drug sector.
What Does Patent BR112019025625 Cover?
Brazilian patent application BR112019025625, published on December 17, 2019, designates AstraZeneca AB as the applicant. The application seeks protection for new crystalline forms of Osimertinib mesylate, a compound known for its efficacy as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Osimertinib is the active pharmaceutical ingredient in Tagrisso®, a targeted therapy for non-small cell lung cancer (NSCLC) with specific EGFR mutations.
The primary focus of the patent application is to claim specific polymorphic forms of Osimertinib mesylate that offer improved physicochemical properties. These properties can translate into enhanced drug formulation, stability, bioavailability, and manufacturing efficiency. By securing patents on these specific crystalline forms, AstraZeneca aims to extend the exclusivity of its Osimertinib franchise beyond the expiration of its primary compound patent.
The technical disclosure within the patent application details:
- The compound: Osimertinib mesylate, identified by its chemical name N-(2-{4-(dimethylamino)piperidin-1-yl}ethyl)-N-methyl-5-(4-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)-2-oxo-1,2-dihydro-pyridin-3-carboxamide methanesulfonate.
- Crystalline forms: The application specifically claims several anhydrous crystalline forms, referred to as Form I, Form II, Form III, Form IV, Form V, and Form VI. These forms are characterized by specific X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) profiles, and other spectroscopic data.
- Manufacturing processes: Methods for producing these specific crystalline forms are also described, which are essential for claiming the forms themselves.
- Pharmaceutical compositions: The patent also covers pharmaceutical compositions containing these novel crystalline forms, including formulations like tablets and capsules.
- Therapeutic uses: The application asserts the use of these crystalline forms in the treatment of EGFR-mutated NSCLC.
The scope of protection sought is broad, encompassing not only the specific crystalline forms but also compositions and methods of use related to them. This strategic patenting approach is common in the pharmaceutical industry to build a robust intellectual property portfolio around a blockbuster drug.
What Are the Key Claims of BR112019025625?
The patent application BR112019025625 outlines several claims that define the boundaries of the intellectual property rights sought by AstraZeneca AB. The claims are meticulously drafted to cover specific crystalline forms and their therapeutic applications.
The claims can be broadly categorized as follows:
- Claims directed to specific crystalline forms: These are the core of the patent. They define novel anhydrous crystalline forms of Osimertinib mesylate. Each form is characterized by a unique set of diffraction peaks in an X-ray powder diffraction (XRPD) pattern, along with other physical properties. For instance, a claim might define a specific crystalline form by its XRPD data, including the d-spacings and relative intensities of its major peaks.
- Claims directed to processes for preparing these crystalline forms: These claims protect the methods used to manufacture the specific polymorphic forms. This prevents competitors from using patented processes to generate the claimed crystalline forms, even if they are not explicitly covered by a compound or composition claim.
- Claims directed to pharmaceutical compositions: These claims cover formulations that incorporate the novel crystalline forms of Osimertinib mesylate. This includes claims for tablets, capsules, or other dosage forms containing a therapeutically effective amount of the active ingredient and at least one pharmaceutically acceptable excipient.
- Claims directed to therapeutic uses: These claims cover the use of the claimed crystalline forms in treating specific medical conditions, primarily EGFR-mutated non-small cell lung cancer. This can include claims for methods of treating such conditions by administering a therapeutically effective amount of the claimed crystalline form.
The specific wording of the claims is crucial for determining infringement. For example, a claim might read:
- "An anhydrous crystalline form of Osimertinib mesylate, characterized by an X-ray powder diffraction pattern comprising peaks at the following 2-theta values (±0.2° 2-theta): 6.3, 10.7, 14.6, 18.2, 20.8, 22.3, 24.5, 26.8."
The exact number of claims and their specific definitions would be detailed in the formal patent document. However, the general intent is to protect the unique physical manifestations of Osimertinib mesylate and their utility, thereby reinforcing AstraZeneca's market position for Tagrisso®.
What Is the Patent Landscape for Osimertinib in Brazil?
The patent landscape for Osimertinib in Brazil is characterized by a strategic portfolio of intellectual property designed to protect the drug from its inception through its lifecycle. AstraZeneca AB, as the innovator, has established a comprehensive patent strategy that includes not only the active pharmaceutical ingredient (API) itself but also its various salt forms, crystalline polymorphs, formulations, and methods of use.
Key elements of the patent landscape include:
- Primary compound patent: The original patent covering the Osimertinib molecule itself. This is typically the first layer of protection.
- Salt and Polymorph patents: Patents like BR112019025625 cover specific crystalline forms (polymorphs) and potentially salt forms of Osimertinib mesylate. These are crucial for lifecycle management, as they can extend market exclusivity beyond the expiry of the original compound patent.
- Formulation patents: These protect specific drug delivery systems or dosage forms that enhance the efficacy, safety, or patient compliance of Osimertinib.
- Method of use patents: Patents covering the use of Osimertinib for treating specific indications, particularly those defined by genetic markers like EGFR mutations.
Key players and their potential strategies:
- AstraZeneca AB: As the originator, AstraZeneca holds the primary patents and is actively seeking to broaden its protection through secondary patents such as BR112019025625. Their strategy focuses on maintaining market exclusivity for Tagrisso® for as long as possible by blocking generic entry through a robust patent portfolio.
- Generic manufacturers: Companies aiming to launch generic versions of Osimertinib will meticulously analyze AstraZeneca's patent portfolio. They will seek to identify patents that have expired, are invalid, or can be circumvented through alternative non-infringing crystalline forms, formulations, or manufacturing processes. The existence of patents on specific polymorphs, like those in BR112019025625, presents a significant hurdle for generic manufacturers, requiring them to develop non-infringing alternatives.
- Other pharmaceutical companies: Competitors developing next-generation EGFR inhibitors or alternative treatments for NSCLC will operate within this patent landscape, being mindful of existing patents and seeking to innovate in areas not covered by current protections.
Regulatory considerations in Brazil:
Brazil's patent law, governed by the National Institute of Industrial Property (INPI), follows international norms. However, there can be specific nuances in examination and enforcement. The patentability criteria (novelty, inventive step, industrial applicability) are applied by INPI examiners. For secondary patents like those covering polymorphs, demonstrating a significant technical advantage over known forms is crucial for patentability.
The effective patent term in Brazil is generally 20 years from the filing date for patents and 10 years for utility models, with a minimum term of 7 years from the grant date for patents. However, there are provisions for patent term extension (PTE) under specific circumstances, which could further extend market exclusivity.
The landscape for Osimertinib is dynamic. As patents approach expiration or face challenges, the risk of generic competition increases. Companies like AstraZeneca proactively file for secondary patents to create a "patent thicket" that delays or deters generic entry. Analyzing each patent, including its claims and validity, is essential for any stakeholder.
What Are the Implications of Patent BR112019025625 for Market Entry?
The implications of patent BR112019025625 for market entry in Brazil are significant, particularly for generic drug manufacturers and any entities seeking to develop or market Osimertinib-based products. This patent, focusing on novel crystalline forms of Osimertinib mesylate, represents a crucial layer of intellectual property protection for AstraZeneca AB.
For Generic Manufacturers:
- Direct Infringement Risk: Any generic manufacturer seeking to produce or sell Osimertinib mesylate in Brazil must carefully assess whether their proposed product utilizes any of the crystalline forms claimed in BR112019025625. If a generic product incorporates a claimed crystalline form without a license, it constitutes direct infringement of the patent.
- Need for Non-Infringing Alternatives: Generic companies will need to invest in R&D to identify or develop alternative crystalline forms of Osimertinib mesylate that are not covered by the patent's claims. This requires extensive characterization and patent landscape analysis to ensure freedom to operate. The expense and time involved in developing and validating such alternatives can significantly delay market entry.
- Formulation and Manufacturing Challenges: Even if a non-infringing crystalline form is developed, manufacturers must also ensure their formulations and manufacturing processes do not infringe other patents held by AstraZeneca, including those related to specific drug compositions or production methods.
- Potential for Patent Litigation: If a generic manufacturer proceeds with a product that AstraZeneca believes infringes BR112019025625 or other related patents, it could trigger patent litigation. Such disputes are costly, time-consuming, and can result in injunctions preventing market entry and significant damages.
For AstraZeneca AB:
- Extended Market Exclusivity: This patent, by protecting specific advantageous crystalline forms, allows AstraZeneca to extend the commercial lifespan of its Osimertinib franchise beyond the expiration of its primary compound patent. This secures continued revenue streams from Tagrisso® in the Brazilian market.
- Strengthened Market Position: The patent acts as a deterrent to potential competitors, reinforcing AstraZeneca's market dominance in the EGFR inhibitor segment for NSCLC.
- Licensing Opportunities: While primarily a defensive measure, AstraZeneca could potentially leverage this patent for strategic licensing agreements with other parties interested in specific crystalline forms or related technologies.
For Investors and Stakeholders:
- Risk Assessment: Investors in generic pharmaceutical companies must carefully evaluate the patent landscape in Brazil, including patents like BR112019025625, to understand the timelines and risks associated with generic product launches.
- Opportunity Identification: Conversely, for investors focused on the innovator side, such patents represent successful R&D and strategic intellectual property management, underpinning the long-term value of a pharmaceutical asset.
- Market Dynamics: The presence and strength of secondary patents influence pricing, competition, and overall market dynamics within the oncology therapeutic area in Brazil.
Key Dates and Timelines:
- Filing Date: The patent application BR112019025625 was filed, establishing its priority date.
- Publication Date: December 17, 2019. This made the details of the application publicly available.
- Grant Date: The date when the patent is officially granted by INPI after examination. This date is critical for determining the patent's term of validity.
- Patent Term: The patent will remain in force for a term of 20 years from the filing date, subject to payment of maintenance fees. Any potential patent term extensions would further impact the duration of exclusivity.
Understanding the precise claims and the examination status of BR112019025625 is paramount for any entity operating within the Brazilian pharmaceutical market concerning Osimertinib.
Key Takeaways
- Patent application BR112019025625, filed by AstraZeneca AB, seeks protection for novel crystalline forms of Osimertinib mesylate in Brazil.
- The patent claims specific anhydrous crystalline forms characterized by unique X-ray powder diffraction patterns and other physical properties, alongside manufacturing processes, pharmaceutical compositions, and therapeutic uses.
- This patent represents a critical component of AstraZeneca's strategy to extend market exclusivity for its EGFR inhibitor Osimertinib (Tagrisso®) in Brazil.
- For generic manufacturers, BR112019025625 poses a significant barrier to market entry, necessitating the development of non-infringing crystalline forms and potentially leading to patent litigation.
- The patent landscape for Osimertinib in Brazil is characterized by a layered intellectual property strategy, including compound, polymorph, formulation, and method of use patents.
Frequently Asked Questions
-
What is the primary technical innovation claimed in patent BR112019025625?
The primary technical innovation claimed is the discovery and characterization of specific, novel anhydrous crystalline forms of Osimertinib mesylate that possess advantageous physicochemical properties.
-
When does patent BR112019025625 officially expire in Brazil?
The patent term is typically 20 years from the filing date, with potential for extension under Brazilian law. The exact expiry date will be determined by the official grant date and any granted term extensions.
-
Can a generic company launch an Osimertinib product in Brazil while BR112019025625 is still in force?
A generic company can launch an Osimertinib product only if their product does not infringe any active and valid patents, including BR112019025625. This typically requires developing a non-infringing crystalline form and formulation.
-
How does patent BR112019025625 differ from the original patent for the Osimertinib compound?
This patent protects specific solid-state forms (crystalline polymorphs) of Osimertinib mesylate, whereas the original patent would have covered the Osimertinib molecule itself, regardless of its physical form. Polymorph patents are often filed later to extend exclusivity.
-
What are the potential consequences for AstraZeneca if their claims in BR112019025625 are found to be invalid or are successfully challenged?
If the claims are invalidated or successfully challenged, it would weaken AstraZeneca's market exclusivity for the specific crystalline forms claimed, potentially opening the door for generic competition earlier than anticipated for those specific forms.
Citations
[1] AstraZeneca AB. (2019). Forma cristalina anidra de mesilato de osimertinibe, processo para sua preparacao, composicao farmaceutica e seu uso terapeutico. Brazilian Patent Application BR112019025625. (Publication date: December 17, 2019).
